Positron emission tomography coupled with 2-deoxy-2-18F-fluoro-D-glucose computed tomography (18FDG PET/CT) has become established at various stages of cancer management. The aim of this prospective study, including 60 patients, was to evaluate the contribution of 18FDG PET/CT in an oncologic population that had benefited from this examination. The mean age was 39 years, with a sex ratio of 0.7. The 18FDG PET/CT scan was performed as part of an initial extension workup (13%), early mid-treatment evaluation (5%), end-of-treatment evaluation (49%), recurrence search and workup (29%), and search...